Ying Du Sells 50,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 50,000 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at $17,032,212.99. This trade represents a 9.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total transaction of $1,622,000.00.

Zai Lab Price Performance

NASDAQ:ZLAB traded up $1.03 during trading hours on Friday, hitting $36.42. The stock had a trading volume of 1,312,257 shares, compared to its average volume of 750,101. The company has a 50 day simple moving average of $28.46 and a two-hundred day simple moving average of $26.45. Zai Lab Limited has a one year low of $13.48 and a one year high of $37.99. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of -13.15 and a beta of 1.08.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The company had revenue of $109.07 million for the quarter, compared to analysts' expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZLAB. Cantor Fitzgerald upgraded shares of Zai Lab to a "strong-buy" rating in a report on Tuesday. Scotiabank began coverage on shares of Zai Lab in a research note on Friday. They set a "sector outperform" rating and a $55.00 price target for the company. Finally, Bank of America reaffirmed a "neutral" rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Institutional Trading of Zai Lab

Institutional investors and hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. purchased a new stake in shares of Zai Lab during the 4th quarter valued at $46,172,000. Geode Capital Management LLC raised its position in Zai Lab by 26.4% in the 3rd quarter. Geode Capital Management LLC now owns 43,626 shares of the company's stock worth $1,053,000 after purchasing an additional 9,107 shares during the period. Alberta Investment Management Corp raised its position in Zai Lab by 42.9% in the 4th quarter. Alberta Investment Management Corp now owns 232,293 shares of the company's stock worth $6,084,000 after purchasing an additional 69,740 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Zai Lab by 28.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company's stock worth $4,801,000 after purchasing an additional 41,128 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Zai Lab during the fourth quarter valued at about $511,000. Hedge funds and other institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.